and "statins" may decrease cardiovascular mortality in patients with other cardiovascular conditions, and is advised. The treatment of elderly patients with severe aortic stenosis is difficult.

The only effective treatment for aortic stenosis is removal of the mechanical obstruction. To this end, only aortic valve replacement (AVR) has been shown to achieve this while reducing mortality.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

The clinical significance of a patient with aortic stenosis exhibiting symptoms cannot be underemphasized since the onset of symptoms is accompanied by a dramatic increase in mortality.

In the trial, TAVR, which assists patients suffering from the heart valve disorder aortic stenosis ... shown to have comparable rates of all-cause mortality or disabling stroke.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality ... patients with aortic stenosis, a type of ...

Having any sleep disorder was independently linked to a higher likelihood for developing aortic stenosis, although dyslipidemia appeared to be an important mediator of the risk Data from the ...

Patients with severe aortic stenosis who were treated with either Evolut TAVR or surgery showed comparable rates of all-cause mortality or disabling stroke at 5 years (Evolut TAVR [15.5%] and ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

TAVR is now FDA approved for use in high, intermediate and low surgical risk patients with severe aortic stenosis. Low risk was defined as a predicted 30-day mortality of 3% or less for 30 days ...